» Articles » PMID: 16786526

Significance of T2 Lesions in Multiple Sclerosis: A 13-year Longitudinal Study

Overview
Journal Ann Neurol
Specialty Neurology
Date 2006 Jun 21
PMID 16786526
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the relation between T2 lesions and disease severity in relapsing-remitting multiple sclerosis (MS).

Methods: This article describes a 13-year longitudinal study in 30 patients.

Results: Patients were 36.3 +/- 6.0 years old, had MS for 6.1 +/- 5.8 years, Expanded Disability Status Scale was 2.2 +/- 0.8, and brain parenchymal fraction (BPF) was 0.825 +/- 0.015 at study entry. At last visit, Expanded Disability Status Scale was 4.4 +/- 1.95, Multiple Sclerosis Functional Composite was -0.34 +/- 1.7, and BPF was 0.774 +/- 0.037. Baseline T2 lesion volume correlated with the BPF of the last visit (r = -0.66; p < 0.0001), magnetization transfer ratio (MTR) in normal-appearing brain tissue (r = -0.52; p = 0.004), and lesion MTR (r = -0.76; p < 0.0001). Change in T2 lesion volume in the first 2 years correlated with BPF of the last visit (r = -0.40; p = 0.03), normal-appearing brain tissue MTR (r = -0.44; p = 0.015), lesion MTR (r = -0.46; p = 0.018), Multiple Sclerosis Functional Composite scores (r = -0.50; p = 0.005), and Paced Auditory Serial Addition Task scores (r = -0.52; p = 0.003). Age was a significant covariate for clinical but not magnetic resonance imaging outcomes.

Interpretation: T2 lesions in relapsing-remitting MS correlate strongly with brain tissue loss and brain tissue integrity 13 years later, and with clinical disease severity, though age significantly impacts the clinical correlation. The results provide direct evidence for the disability threshold hypothesis in MS and support monitoring T2 lesions in relapsing-remitting MS.

Citing Articles

Neuroimaging markers and disability scales in multiple sclerosis: A systematic review and meta-analysis.

Mirmosayyeb O, Yazdan Panah M, Mokary Y, Mohammadi M, Moases Ghaffary E, Shaygannejad V PLoS One. 2024; 19(12):e0312421.

PMID: 39637162 PMC: 11620670. DOI: 10.1371/journal.pone.0312421.


The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis.

Ananthavarathan P, Sahi N, Chung K, Haider L, Prados F, Trip S J Neurol Neurosurg Psychiatry. 2024; .

PMID: 39038948 PMC: 7616528. DOI: 10.1136/jnnp-2024-333917.


Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.

Schaller-Paule M, Maiworm M, Schafer J, Friedauer L, Hattingen E, Wenger K J Neurol. 2024; 271(6):3512-3526.

PMID: 38536455 PMC: 11136815. DOI: 10.1007/s00415-024-12299-z.


Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis.

Hoffmann O, Paul F, Haase R, Kern R, Ziemssen T Patient Prefer Adherence. 2024; 18:455-466.

PMID: 38406376 PMC: 10894675. DOI: 10.2147/PPA.S452849.


Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?.

Hoffmann O, Gold R, Meuth S, Linker R, Skripuletz T, Wiendl H Ther Adv Neurol Disord. 2024; 17:17562864241229325.

PMID: 38332854 PMC: 10851744. DOI: 10.1177/17562864241229325.